Lupin Limited Press Release Jul 31 2026
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Lupin Limited has announced the approval of Diazepam Injection, USP in the United States. This approval is for the company's Abbreviated New Drug Application for a specific formulation of Diazepam. The product is indicated for managing anxiety disorders and is bioequivalent to a reference drug.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Lupin's latest callLupin (NSE:LUPIN) Q2 2027 Earnings Call · Replay · Nov 4Read the transcript of Lupin (NSE:LUPIN) Q2 2027 Earnings CallEarlier from Lupin
- Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection
- Lupin Limited Press Release Jul 14 2026
- Lupin Named Among World's Most Sustainable Companies by TIME and Statista
- Lupin Limited Press Release Jul 06 2026
- Lupin Limited Press Release Jul 01 2026
Later from Lupin
- Lupin Limited Press Release Aug 06 2026
- Lupin Limited Press Release Aug 10 2026
- Lupin Limited Press Release Aug 17 2026
- Lupin Announces Approval from U.S. FDA for Pitolisant Tablets
- Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland
Follow Lupin into a list and get an email when it puts out news.
Follow Lupin